ASS1 and renal carcinoma: The treatment of 786-O with 5-azacitidine (5AC), a DNA demethylating agent, significantly increased ASS1 expression, supporting the hypothesis that ASS1 is epigenetically suppressed in primary renal cancer cells (Fig. 6e).